Galmed Pharmaceuticals Q1 EPS $(0.62) Beats $(0.89) Estimate

Galmed Pharmaceuticals (NASDAQ: GLMD) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.89) by 30.34 percent. This is a 70.48 percent increase over losses of $(2.10) per share from the same period last year.